The honest answer has to lead with how thin the record is: the published human evidence on CJC-1295 is small, dated, and narrow, concentrated in a few early-phase studies from the mid-2000s. CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), and the long-acting form with a drug affinity complex (DAC) binds albumin to stretch the molecule's half-life from minutes to several days. Those studies were built to characterize pharmacokinetics and the hormone response, not to show that the compound improves any clinical outcome, and CJC-1295 is not an approved drug in the United States or comparable jurisdictions.
What is reliably documented for CJC-1295 is limited to short-term, dose-dependent increases in growth hormone and IGF-1 in healthy adults, while the broader body-composition, recovery, and longevity claims attached to the peptide are not supported by any controlled human efficacy trial.
Measured against ordinary drug development, the human literature on CJC-1295 is sparse rather than emerging. The substantive peer-reviewed human work amounts to a handful of early-phase studies, most cited being the 2005-2006 work by Teichman and colleagues, which enrolled healthy adults in the dozens rather than the hundreds. The field has effectively been frozen for well over a decade, since little or no rigorous new human trial data has been published since the mid-2000s cluster.
The substantive human evidence on CJC-1295 rests on a handful of mid-2000s early-phase studies enrolling only dozens of healthy volunteers, with essentially no rigorous new human trial data published in the years since.
The foundational studies were pharmacology studies in the strict sense, tracking what the molecule did to circulating hormones rather than what it did to a person's health. After subcutaneous administration to healthy adults, investigators recorded dose-dependent rises in plasma growth hormone, with mean concentrations climbing severalfold at higher doses, alongside IGF-1 elevations that persisted for roughly one to two weeks after a single injection. What these studies deliberately did not measure is any functional outcome, so the data establish a hormonal mechanism while saying nothing about benefit.
The pivotal human studies measured surrogate endocrine readouts only, documenting severalfold growth hormone increases and one-to-two-week IGF-1 elevation while measuring no clinical or functional outcome whatsoever.
Much of the confusion around CJC-1295 traces to two distinct molecules being discussed under one name. The published human trials concern CJC-1295 with DAC, the long-acting form whose drug affinity complex binds albumin and stretches the half-life to roughly six to eight days; what is widely sold as CJC-1295 without DAC is more accurately modified GRF 1-29, a short-acting GHRH fragment whose half-life is measured in minutes. The distinction matters for interpreting the record, because the clinical pharmacology data belong almost entirely to the DAC version, and evidence generated for one form does not automatically transfer to the other.
| Criteria | CJC-1295 with DAC | Modified GRF 1-29 (without DAC) |
|---|---|---|
| Half-life | Roughly 6 to 8 days | Minutes |
| Albumin-binding complex | Present | Absent |
| Signaling pattern | Continuous GHRH-like stimulation | Brief, sharper pulse closer to endogenous release |
| Published human trial data | Where nearly all of it sits | Not the subject of comparable trials |
The published human pharmacology belongs almost entirely to CJC-1295 with DAC, whose six-to-eight-day half-life and continuous signaling differ fundamentally from the minutes-long modified GRF 1-29, so the two forms cannot be treated as interchangeable.
The gap between what has been studied and what is claimed is the central honesty problem with CJC-1295. The trials that exist measured surrogate endocrine endpoints almost exclusively, including plasma growth hormone, IGF-1 levels, half-life, and basic tolerability, while the clinically meaningful outcomes people actually care about have not been established in controlled human trials. Raising IGF-1 is a surrogate marker, and a surrogate moving in a favorable direction does not by itself prove that any health outcome improves.
Every CJC-1295 human trial measured surrogate endocrine markers such as growth hormone and IGF-1, and no controlled human trial has established any clinically meaningful outcome including muscle gain, fat loss, recovery, sleep, bone density, or metabolic health.
On safety, the human record is short enough that the most important fact is how much remains unknown. The commonly reported effects in the dosing studies were generally mild, local, or transient, including injection-site reactions, flushing, headache, and occasional signs consistent with growth hormone excess such as fluid retention. The more consequential entry is a reported serious adverse event tied to a precursor formulation during early development, widely cited as a contributing reason the program did not advance through later-stage trials.
Observed effects in the short human studies were mostly mild and transient, but a reported serious adverse event in a precursor formulation contributed to the program stalling, and no trial ran long enough to detect the delayed or cumulative harm theorized from sustained growth hormone and IGF-1 elevation.
Even taking the existing studies at face value, their design imposes hard limits on what they can support. The samples were small and the trials short, the participants were generally healthy volunteers rather than the older or clinically affected populations marketing targets, and the endpoints were surrogates by design. Compounding all of this is the near-total absence of independent replication, which leaves a body of evidence resting on a small cluster of early studies from a constrained set of investigators.
The existing trials are constrained by samples of only dozens, durations of days to weeks, healthy-volunteer cohorts, surrogate endpoints, and a near-total absence of independent replication, which together explain why CJC-1295 never entered mainstream clinical practice.
The regulatory record is itself a form of evidence, and what it says is unambiguous: CJC-1295 is not an approved drug for any therapeutic use in the United States or in comparably regulated jurisdictions. It never completed the clinical development pathway approval requires, stalling in early phases rather than advancing to the large confirmatory trials a marketing approval demands. As a result it occupies the gray category of a research chemical, sold for laboratory use and labeled not for human consumption.
CJC-1295 holds no marketing approval in the United States or comparable jurisdictions, is sold as a research chemical labeled not for human consumption, and is banned in and out of competition by anti-doping authorities as a growth hormone secretagogue.
Reading the evidence honestly means naming the large blank spaces it leaves. The most pressing open question is long-term safety, because nothing in the record speaks to what sustained growth hormone and IGF-1 elevation does over months or years, including effects on insulin sensitivity, cardiovascular health, or cancer risk. Equally unanswered is whether the compound produces any genuine clinical benefit, since the efficacy endpoints that matter have never been tested in adequately powered, controlled human trials.
The evidence leaves long-term safety and genuine clinical benefit entirely unanswered, and the early safety history, lost commercial exclusivity, and drift into an unregulated gray market make the funding of the large confirmatory trials that could answer them unlikely.
Educational use only. This article describes what the published scientific and clinical literature reports about CJC-1295. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
